A Pre-IND meeting with the FDA is a Type B interaction you request in writing once your preclinical program is far enough along to support first-in-human testing but before you file the Investigational New Drug application. The agency targets a 21-day response to the request and schedules the meeting within 60 calendar days.1U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Preparation runs on two documents: a short meeting request that gets you on the calendar, and a detailed briefing package that must reach the review division at least four weeks before the meeting date.
Are You Ready to Request One
Eligibility turns on data readiness. You qualify when you have completed enough pharmacology and toxicology work in animal models to make a reasonable case that the drug is safe enough for initial human testing. That typically means finished primary toxicology studies, a basic understanding of how the drug behaves in the body, early evidence of the intended therapeutic effect, and the ability to manufacture the drug consistently enough for clinical use.
If your product is still at the proof-of-concept stage and you haven’t started definitive toxicology studies, you’re probably too early. The FDA may deny the request as premature and steer you toward an INTERACT meeting, which is designed for sponsors who have identified their investigational product and run preliminary preclinical proof-of-concept studies but haven’t yet designed or conducted definitive toxicology work.2U.S. Food and Drug Administration. OTP INTERACT Meetings On the other end, if you’ve already designed everything and just want the agency to preview your IND, that’s also likely to be denied. The Pre-IND meeting exists for genuine scientific and regulatory questions, not a dress rehearsal of the submission.
One boundary worth confirming before you spend time on any of this: not every clinical investigation requires an IND. Studies involving a lawfully marketed drug are exempt when the study isn’t intended to support a new indication or significant labeling change, doesn’t meaningfully increase the drug’s risk profile, and complies with institutional review board and informed consent rules.3eCFR. 21 CFR 312.2 – Applicability Studies involving placebos alone and purely in vitro or laboratory research are also exempt. If your investigation falls into one of these categories, you don’t need an IND and don’t need a Pre-IND meeting.
What Goes in the Meeting Request
The meeting request is a written submission separate from the briefing package. It needs to contain enough information for the FDA to evaluate whether the meeting is appropriate and to assign the right review team. The formal meetings guidance calls for these elements:
- Product identification, including the name, chemical structure, and any application numbers previously assigned by the FDA.
- The proposed indication: the specific disease or condition the drug is intended to treat.
- Meeting objectives, stated clearly, so the agency understands what you hope to resolve.
- Specific questions on regulatory or scientific hurdles. Vague requests for general feedback weaken the submission and are grounds for denial.
- An attendee list with names, titles, and roles of everyone you plan to have in the room.
- A brief product summary describing the drug and its development status, enough for the agency to gauge readiness.
Form FDA 1571 is the cover sheet for an IND application, not the meeting request.4U.S. Food and Drug Administration. IND Forms and Instructions Your Pre-IND meeting request is its own document formatted according to the FDA’s formal meetings guidance.
Building the Briefing Package
The briefing package is the real substance of the interaction, and its deadline is firm. For Type B meetings, the review division must receive the package at least four weeks before the scheduled meeting date.5Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants – Guidance for Industry Missing that deadline can result in postponement or cancellation.
The chemistry, manufacturing, and controls section describes the drug’s physical and chemical properties, how it’s produced, the methods used to ensure batch-to-batch consistency, and the stability data supporting its shelf life. Reviewers want to see that the manufacturing process can reliably eliminate impurities and produce a drug of known potency. The detail level doesn’t need to reach what a New Drug Application requires, but it does need to show a credible manufacturing operation.
The preclinical pharmacology and toxicology section summarizes the animal-study results: effects at different dose levels, how the body absorbs and eliminates the drug, and any toxic responses observed during testing. The FDA uses this data to evaluate whether the proposed starting dose and dose-escalation plan in humans are reasonable.
The package should also include the proposed Phase 1 clinical protocol, covering study design, participant selection criteria, dosing schedule, safety monitoring procedures, and the number of subjects. Organize the whole package with a table of contents and clear section headings. A disorganized package that forces reviewers to hunt for information leads to less useful feedback in the limited time they have.
FDA Response and Scheduling
Within 21 calendar days of receiving your request, the FDA sends a response indicating whether the request has been granted, denied, or needs modification.1U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products The response also confirms the format. Meetings can take place in person, by videoconference, by teleconference, or as a Written Response Only.
A Written Response Only means the FDA answers your questions in writing without holding an actual meeting. This is more common than many sponsors expect, particularly when the agency believes the questions can be adequately addressed on paper. If you strongly prefer a live discussion, make that case in the meeting request, but the final decision on format rests with the agency.
When a live meeting is scheduled, it typically takes place within 60 calendar days of the FDA’s receipt of the original request.1U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products The agency’s multidisciplinary review team uses the intervening weeks to analyze your briefing package. The FDA generally provides its preliminary responses to your questions roughly two days before the meeting, which lets you focus the live discussion on areas of disagreement or remaining uncertainty rather than hearing the agency’s positions for the first time in the room.
How to Prepare for the Meeting Itself
The meeting follows a tight agenda built around the questions you submitted. The FDA opens by walking through its preliminary responses, and the discussion focuses on clarifying the agency’s expectations for the upcoming IND submission, flagging safety concerns, and resolving technical issues that could delay the start of clinical trials. It isn’t an open-ended brainstorm. Sponsors who arrive with follow-up questions prepared for each agenda item get far more value than those who treat it as a general conversation.
FDA participants typically include reviewers from chemistry and manufacturing, pharmacology and toxicology, clinical medicine, and biostatistics. Bring people who can speak substantively to each of those areas rather than loading the room with executives who can’t answer technical follow-ups. The most productive Pre-IND meetings happen when both sides have decision-makers present who can agree on a path forward in real time.
Why Requests Get Denied
You generally get one Pre-IND meeting per product per clinical indication, so understanding the FDA’s grounds for denial matters before you submit:
- The meeting request is missing required elements from the formal meetings guidance.
- The development program is premature. The agency may suggest an INTERACT meeting instead.
- The questions focus only on jurisdictional issues, such as whether the product is regulated as a drug, device, or biologic.
- The request contains no specific questions. General requests for guidance aren’t enough.
- The requestor doesn’t intend to sponsor clinical studies under an IND and instead plans to manufacture a product for other investigators to use.
- A Pre-IND meeting has already been held for the product. A second meeting to preview the IND submission won’t be approved.
- All questions address a single review discipline. Pre-IND meetings are meant to cover the full development program across interdependent disciplines.
These criteria come from FDA guidance specific to the Office of Therapeutic Products at CBER, but they reflect the general principles the agency applies across review centers.6Food and Drug Administration. OTP Pre-IND Meetings If a request is denied for anything other than a prior meeting already held, you can usually address the deficiency and resubmit.
After the Meeting
The FDA issues official minutes within 30 calendar days of the meeting.1U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Those minutes are the agency’s formal record of what was discussed, what was agreed upon, what remained unresolved, and what action items each side committed to. They carry real weight. The FDA will reference them when reviewing your eventual IND submission, and any deviation from the agreed development plan will require explanation.
Review the minutes carefully as soon as they arrive. If they don’t accurately reflect what was discussed or agreed to, contact the assigned Regulatory Project Manager to flag the discrepancies. For formal clarification of the FDA’s responses, you can submit a Request for Clarification within 20 calendar days of receiving the minutes. The request may only include clarifying questions about what the agency already said; new questions aren’t permitted through this channel. The FDA responds in writing within 20 calendar days of receiving the clarification request.7U.S. Food and Drug Administration. Formal Meetings and Requests for Feedback for CBER-Regulated Products For a narrow question limited to a single review discipline, you can route the question through the Regulatory Project Manager, and the FDA typically responds by email within three business days.
Because you generally get only one Pre-IND meeting per product per clinical indication, additional guidance needs typically go into the IND itself rather than a second Pre-IND request.8U.S. Food and Drug Administration. OTP Pre-IND Meetings The IND review process has its own mechanisms for FDA feedback, including clinical holds and information requests. Map each piece of Pre-IND feedback to a specific section of the IND, and when you disagree with something the agency asked for or can’t provide it, explain the rationale for the alternative rather than ignoring the request.
If your product may eventually be used in children, raise pediatric strategy briefly at the Pre-IND stage even though the formal obligation comes later. The initial Pediatric Study Plan must be submitted no later than 60 calendar days after the end-of-Phase 2 meeting or, if no such meeting occurs, before Phase 3 studies begin.9U.S. Food and Drug Administration. Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Surfacing agency expectations early can shape the entire development timeline.